on VALBIOTIS (EPA:ALVAL)
Valbiotis Expands in the Middle East with Qatar Distribution Deal
French laboratory Valbiotis has announced an exclusive distribution agreement with Al Danah Medical Company in Qatar. This deal marks another milestone in Valbiotis' expansion in the Middle East. Al Danah, a leader in Qatar's healthcare and nutrition sector, will handle the launch of four Valbiotis products, including ValbiotisPRO® and Steadrive®.
The partnership foresees product registration, distribution, and promotion handled by Al Danah. Their market knowledge should facilitate successful entry into the Qatari market, where cardiometabolic health issues are prevalent. Expected revenues are anticipated as early as 2027.
This move aligns with Valbiotis' international strategy, following recent deals in Asia and the Middle East. Sébastien Peltier, CEO, highlights Qatar's rapid healthcare sector growth and demand for preventive solutions as driving factors for the agreement's potential success.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news